Surgery Partners
SGRY on Nasdaq. Surgery Partners sells surgical care at outpatient facilities to patients and physicians. Market value $1.7bn.
Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.
Should I look at this?
Worth a closer look
Why it could be worth it
What to watch out for
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $10.69 of spare cash in the past 12 months. A savings account pays about $4.
You pay 13.8 years of operating profit for the business. The average large US company costs around 18.
Each dollar kept in the business earns 6 cents a year. Above 10 is good.
Quality score: 72 of 100. Price score: 63 of 100. Our list needs 70 on quality and 60 on price.
$13.41 a share, 18% above its 1-year low
Over the past year the price has ranged from $11.41 to $23.44.
Pays no dividend
Prices from Tuesday’s close (6 October).
Five years of cash, in billions
| Revenue | |||||
| Revenue | $2.2bn | $2.5bn | $2.7bn | $3.1bn | $3.3bn |
| Operating margin | |||||
| Operating margin | 13.6% | 13.6% | 12.0% | 11.2% | 11.8% |
| Debt to equity | |||||
| Debt to equity | 2.70 | 1.31 | 1.40 | 1.88 | 2.16 |
| Shares outstanding | |||||
| Shares outstanding | 0.09bn | 0.13bn | 0.13bn | 0.13bn | 0.13bn |
Health checks
- Free cash flow positive5 of 5 years
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)4 of 8 checks we could run
- Profit backed by cash (accruals)Yes
- Debt2.16× equity
- Revenue growth, five yearsStrong, 12.2% a year
- Buying back its own sharesNo, 46% more shares since 2021
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $849 million last quarter, up 3% on a year ago.
- A loss of $15 million, compared with a loss of $3 million a year ago.
- It keeps 11 cents of each $1 of sales as operating profit, about the same as a year earlier.
- Spare cash over the past 12 months: $188 million, up from $175 million.
- 1% more shares than a year ago. Each share owns a bit less of the company.
- Debt is $3.5 billion more than cash, up from $3.3 billion a year ago.
- Sales grew on a year ago in each of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| September 2024 | $770m |
| December 2024 | $864m |
| March 2025 | $776m |
| June 2025 | $826m |
| September 2025 | $822m |
| December 2025 | $885m |
| March 2026 | $811m |
| June 2026 | $849m |
| Quarter to | Amount |
|---|---|
| September 2024 | -$32m |
| December 2024 | -$109m |
| March 2025 | -$38m |
| June 2025 | -$3m |
| September 2025 | -$23m |
| December 2025 | -$15m |
| March 2026 | -$36m |
| June 2026 | -$15m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 2 March 2026
- Next quarterly (estimated, 10-Q)
- 9 November 2026
Who owns it
1 long-term investor we follow owns it, down from 2 last quarter. 187 funds in all.
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| Oaktree Capital ManagementHoward Marks | $14m | 0.4% | New |
Sold out this quarter
- Glenview Capital ManagementLarry RobbinsSold out
- Irenic CapitalAdam KatzSold out
Largest holders overall
- Bain Capital Investors$839m
- Jupiter Topco$233m
- Pentwater Capital Management LP$195mCut
- UBS Group AG$144mCut
- BlackRock$105mAdded
- King Street Capital Management, L.P.$102mCut
- T. Rowe Price Investment Management$99mAdded
- Dimensional Fund Advisors LP$83mCut
- Clearbridge Investments$64mCut
- Vanguard Portfolio Management$63mAdded
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
5 investors own more than 5%.
- BCPE Seminole Holdings II Intermediate, LPStrategic holderat least 23.4%−0.1 pts(filed with 3 related holders)Since 16 June 2025
What they said
Item 4 of the Initial Statement is hereby amended and supplemented by adding the following at the end of Item 4 of the Initial Statement: On the evening of January 27, 2025, Bain Capital Private Equity, LP, the investment advisor to funds invested through the Reporting Persons,…
Read the filing - JANUS HENDERSON GROUP PLCPassive investorat least 10.2%+0.1 pts(filed with 1 related holder)Since 30 September 2025
- Pentwater Capital Management LPPassive investorat least 9.7%+2.0 pts(filed with 1 related holder)Since 31 March 2026
- Wellington Management Company LLPPassive investor5.4%Since 31 March 2025
- King Street Capital Management, L.P.Passive investorat least 4.6%−2.6 pts(filed with 2 related holders)Since 30 June 2026
- BlackRock, Inc.Passive investorSold down below 5%Since 31 March 2025
- FMR LLCPassive investorSold down below 5%Since 31 March 2026
- The Vanguard GroupPassive investorSold down below 5%Since 13 March 2026
- Wellington Management Group LLPPassive investorSold down below 5%Since 30 June 2025
| Holder | Stake | Since | |
|---|---|---|---|
BCPE Seminole Holdings II Intermediate, LP Strategic holder | at least 23.4%−0.1 pts (filed with 3 related holders) | 16 June 2025 | What they saidItem 4 of the Initial Statement is hereby amended and supplemented by adding the following at the end of Item 4 of the Initial Statement: On the evening of January 27, 2025, Bain Capital Private Equity, LP, the investment advisor to funds invested through the Reporting Persons,… Read the filing |
JANUS HENDERSON GROUP PLC Passive investor | at least 10.2%+0.1 pts (filed with 1 related holder) | 30 September 2025 | |
Pentwater Capital Management LP Passive investor | at least 9.7%+2.0 pts (filed with 1 related holder) | 31 March 2026 | |
Wellington Management Company LLP Passive investor | 5.4% | 31 March 2025 | |
King Street Capital Management, L.P. Passive investor | at least 4.6%−2.6 pts (filed with 2 related holders) | 30 June 2026 | |
BlackRock, Inc. Passive investor | Sold down below 5% | 31 March 2025 | |
FMR LLC Passive investor | Sold down below 5% | 31 March 2026 | |
The Vanguard Group Passive investor | Sold down below 5% | 13 March 2026 | |
Wellington Management Group LLP Passive investor | Sold down below 5% | 30 June 2025 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 1 insider bought $161,213 of shares on the open market. 6 sold $1m.
- DeLuca TeresaDirectorBought
- Date
- 18 August 2026
- Shares
- 11,250
- Price
- $14.33
- Value
- $161,213
- Doherty David TChief Financial OfficerSold
- Date
- 16 March 2026
- Shares
- 8,867
- Price
- $12.50
- Value
- $110,838
- Evans Jason EricChief Executive OfficerSold
- Date
- 16 March 2026
- Shares
- 20,400
- Price
- $12.47
- Value
- $254,388
- Burkhalter DanielleChief Human Resources OfficerSold
- Date
- 13 March 2026
- Shares
- 3,469
- Price
- $12.83
- Value
- $44,507
- Brittenham MarissaChief Strategy OfficerSold
- Date
- 13 March 2026
- Shares
- 3,657
- Price
- $12.54
- Value
- $45,859
- Baldock JenniferChief Admin & Dev OfficerSold
- Date
- 12 March 2026
- Shares
- 5,798
- Price
- $13.17
- Value
- $76,360
- Evans Jason EricChief Executive OfficerSold
- Date
- 6 March 2026
- Shares
- 11,462
- Price
- $13.79
- Value
- $158,061
- Doherty David TChief Financial OfficerSold
- Date
- 6 March 2026
- Shares
- 14,574
- Price
- $13.84
- Value
- $201,704
- Baldock JenniferChief Admin & Dev OfficerSold
- Date
- 6 March 2026
- Shares
- 10,082
- Price
- $13.70
- Value
- $138,123
- Burkhalter DanielleChief Human Resources OfficerSold
- Date
- 6 March 2026
- Shares
- 7,736
- Price
- $13.60
- Value
- $105,210
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 18 August 2026 | DeLuca Teresa Director | Bought | 11,250 | $14.33 | $161,213 |
| 16 March 2026 | Doherty David T Chief Financial Officer | Sold | 8,867 | $12.50 | $110,838 |
| 16 March 2026 | Evans Jason Eric Chief Executive Officer | Sold | 20,400 | $12.47 | $254,388 |
| 13 March 2026 | Burkhalter Danielle Chief Human Resources Officer | Sold | 3,469 | $12.83 | $44,507 |
| 13 March 2026 | Brittenham Marissa Chief Strategy Officer | Sold | 3,657 | $12.54 | $45,859 |
| 12 March 2026 | Baldock Jennifer Chief Admin & Dev Officer | Sold | 5,798 | $13.17 | $76,360 |
| 6 March 2026 | Evans Jason Eric Chief Executive Officer | Sold | 11,462 | $13.79 | $158,061 |
| 6 March 2026 | Doherty David T Chief Financial Officer | Sold | 14,574 | $13.84 | $201,704 |
| 6 March 2026 | Baldock Jennifer Chief Admin & Dev Officer | Sold | 10,082 | $13.70 | $138,123 |
| 6 March 2026 | Burkhalter Danielle Chief Human Resources Officer | Sold | 7,736 | $13.60 | $105,210 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
None of the warning signs we check for were found.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 2 Mar 2026, plus the 10-Q filed 10 Aug 2026 and 5 later 8-Ks.
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
- It carries a lot of debt: 2.2× its equity.
Whether the price already reflects the risks is what the deep dive is for.
What changed in the risks this year
Companies must list what could hurt them each year. These are the parts that changed since last year’s report.
We cannot predict the effect that changes in healthcare laws, regulations, policies and government programs may have on our business, financial condition or results of operations.
Could happenOver the past several years, various laws and regulations lengthened the enrollment period, expanded income eligibility, and reduced premium caps for subsidies for individuals purchasing Affordable Care Act coverage through state and federal marketplaces. However, several of these provisions – notably, those relating to premium caps for subsidies – expired on December 31, 2025. The failure of Congress to renew these subsidies through legislative action is widely anticipated to result in significant increases in premiums, potentially leading to decreased enrollment and a corresponding rise in the number of uninsured individuals or a shift of individuals from commercial coverage to government program coverage in 2026. As a direct effect of these changes, the Company may experience decreased patient volumes, reduced revenues and an increase in uncompensated care, which would adversely affect the Company’s results of operations and cash flows. We cannot predict whether or how the Congress may further extend (or decline to extend) or modify provisions of or relating to the Affordable Care Act or other laws affecting the healthcare industry generally, nor can we predict how the current administration will influence, promulgate or implement rules, regulations or executive orders that affect the healthcare industry directly or indirectly (including, for example, through changes resulting from the provisions of the OBBBA). We may also experience potential impacts on our business, in ways we cannot anticipate, from healthcare-related policy changes at the state level. Some federal and state changes, initiatives and requirements could, among other things, negatively impact our patient volumes, case mix and revenue mix, increase our operating costs, adversely affect the reimbursement we receive for our services, impact our competitive position or require us to expend resources to modify certain aspects of our operations, any of which could have an adverse effect on our financial condition, results of operations or cash flows. Furthermore, we cannot predict the impact healthcare policy risks and uncertainties may have on the trading price of our common stock.
Read more
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.